Does the drug-eluting platform matter?

Session comprising selected EuroPCR 2015 abstract submissions

Presentations available when logged in:

  • Vascular response to everolimus and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds: an OCT substudy of the EVER...
  • The first establishment of early-healing profile and 9-month outcomes of a new polymer-free biolimus-A9 drug-coated stent by longitudinal sequentia...
  • Incidence and characteristics of late catch-up phenomenon between sirolimus-eluting stent and everolimus-eluting stent: a propensity matched study
  • Coverage and apposition of bioabsorbable scaffolds assessed by OCT: the ALSTER-OCT ABSORB registry
  • Coronary evaginations and peri-stent aneurysms following implantation of bioresorbable scaffolds: incidence and OCT analysis of possible mechanisms
  • Comparative study with OCT at 6 and 12 months between DES of resorbable polymer and drug-eluting scaffolds with completely bioresorbable platform i...